Latest Tax Refunds News

Page 1 of 23
Neurizon has opened a non-underwritten A$2 million share purchase plan at A$0.068 a share, giving eligible shareholders access to the same terms as its recent placement. Participants may also receive one free option for each new share, subject to shareholder approval and ASX quotation conditions, as the company funds its NUZ-001 ALS program towards a late Q2 2027 readout.
Ada Torres
Ada Torres
16 Nov 2026
Delorean has reached Financial Close on its $62.1 million NSW1 Horsley Park bioenergy facility, activating $30.5 million of government grants and a 25-year Brickworks gas supply agreement. Procurement can now begin, with construction targeted for early 2027, although Tanarra’s debt documentation and the project’s funding mix still warrant attention.
Victor Sage
Victor Sage
9 Nov 2026
Verisk delivered stronger underlying growth in the third quarter, with organic constant-currency revenue up 7.4% and adjusted EPS rising 14%. But free cash flow fell sharply, while the company continued an aggressive share-repurchase program and kept its 2026 guidance unchanged.
Sophie Babbage
Sophie Babbage
5 Nov 2026
Delorean’s flagship Salisbury bioenergy plant is 90% complete and now licensed to operate, while a proposed A$20 million Westpac facility could unlock its next major project. The catch is a quarterly operating cash outflow of A$2.52 million, leaving 2.52 quarters of funding on the company’s own calculation.
Victor Sage
Victor Sage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
RocketBoots has begun installing its global retail contract in US stores and received its first payment, but quarterly operating cash outflows of A$1.75 million left the company with an estimated 1.03 quarters of funding. Management is relying on incoming customer receipts, an R&D tax refund and a new A$5 million invoice financing facility to support the rollout.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Kingsland Minerals ended the September quarter with $752,000 in cash and estimated funding for less than one quarter at current outgoings. Discussions with major shareholder Quinbrook remain non-binding, while the company has paused Leliyn exploration and is considering drilling its gold and uranium projects.
Maxwell Dee
Maxwell Dee
30 Oct 2026
Micro-X has reported a sharp improvement in Rover order activity and more than $3 million in annualised cost savings, while redirecting its strategy towards medical CT. The September quarter still consumed $4.4 million in operating cash, leaving funding dependent on further note proceeds, an expected tax refund and milestone receipts.
Victor Sage
Victor Sage
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive